Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
Mikhail Kosiborod, Russell Esterline, Remo H.M. Furtado, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 9, pp. 586-594
Open Access | Times Cited: 211

Showing 1-25 of 211 citing articles:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1176
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Peter Rossing, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. S1-S127
Open Access | Times Cited: 724
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 680
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Colin Baigent, Jonathan Emberson, Richard Haynes, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1788-1801
Open Access | Times Cited: 611
Type 2 diabetes
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1803-1820
Closed Access | Times Cited: 587
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 327
COVID-19, Hyperglycemia, and New-Onset Diabetes
Kamlesh Khunti, Stefano Del Prato, Chantal Mathieu, et al.
Diabetes Care (2021) Vol. 44, Iss. 12, pp. 2645-2655
Open Access | Times Cited: 280
COVID-19 and metabolic disease: mechanisms and clinical management
Charlotte Steenblock, Peter E. H. Schwarz, Barbara Ludwig, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 11, pp. 786-798
Open Access | Times Cited: 212
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 154
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
Daniela Tomasoni, Gregg C. Fonarow, Marianna Adamo, et al.
European Journal of Heart Failure (2021) Vol. 24, Iss. 3, pp. 431-441
Open Access | Times Cited: 108
Diabetes and the COVID-19 pandemic
Kamlesh Khunti, Jonathan Valabhji, Shivani Misra
Diabetologia (2022) Vol. 66, Iss. 2, pp. 255-266
Open Access | Times Cited: 80
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 78
Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment
R. I. G. Holt, Clive S. Cockram, Ronald C.W., et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1168-1180
Open Access | Times Cited: 41
Applications of SGLT2 inhibitors beyond glycaemic control
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 8, pp. 513-529
Closed Access | Times Cited: 26
SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials
Marco Valerio Mariani, Giovanna Manzi, Nicola Pierucci, et al.
Journal of Cardiovascular Electrophysiology (2024) Vol. 35, Iss. 9, pp. 1754-1765
Closed Access | Times Cited: 23
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Daniel J. Drucker
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 338-353
Open Access | Times Cited: 22
Diabetes and COVID-19; A Bidirectional Interplay
Paraskevi Kazakou, Vaia Lambadiari, Ignatios Ikonomidis, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 66
Increased Risk of COVID-19 in Patients with Diabetes Mellitus—Current Challenges in Pathophysiology, Treatment and Prevention
Tomasz Gęca, Kamila Wojtowicz, Paweł Guzik, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 11, pp. 6555-6555
Open Access | Times Cited: 63
Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
Natalie Staplin, Alistair Roddick, Jonathan Emberson, et al.
EClinicalMedicine (2021) Vol. 41, pp. 101163-101163
Open Access | Times Cited: 57
Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
Rosalba La Grotta, Chiara Frigé, Giulia Matacchione, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12325-12325
Open Access | Times Cited: 39
COVID-19: Diabetes Perspective—Pathophysiology and Management
Siva Dallavalasa, SubbaRao V. Tulimilli, Prakash Janhavi, et al.
Pathogens (2023) Vol. 12, Iss. 2, pp. 184-184
Open Access | Times Cited: 24
Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study
Han Eol Jeong, Sohee Park, Yunha Noh, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 23
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Amr E. Abbas, Fatima Abbas, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 12, pp. 905-914
Open Access | Times Cited: 23
Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction
Caio A.M. Tavares, Luciano César Pontes Azevedo, Álvaro Réa-Neto, et al.
JAMA (2024) Vol. 332, Iss. 5, pp. 401-401
Closed Access | Times Cited: 16
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
P. Natale, David J. Tunnicliffe, Tadashi Toyama, et al.
Cochrane library (2024) Vol. 2024, Iss. 5
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top